Next Article in Journal / Special Issue
Statistical Properties in Jazz Improvisation Underline Individuality of Musical Representation
Previous Article in Journal
Welcome to the New Open Access NeuroSci
Open AccessArticle

Hematological Alterations Related to Treatment with Teriflunomide and Dimethyl Fumarate in Multiple Sclerosis

Neurology Service, University Hospital of Ourense, 32005 Ourense, Spain
NeuroSci 2020, 1(1), 17-23; https://doi.org/10.3390/neurosci1010003
Received: 8 August 2020 / Revised: 6 September 2020 / Accepted: 16 September 2020 / Published: 21 September 2020
(This article belongs to the Special Issue Feature Papers in Neurosci)
The exact mechanism of action of different modifying treatments in the evolutionary course of multiple sclerosis (MS) remains unknown, but it is assumed that they act upon the cells involved in acquired immunity. One effect of these treatments is the development of lymphopenia, which carries inherent safety risks. This study was conducted to understand the alterations that teriflunomide (TERI) and dimethyl fumarate (DMF) exert upon white blood cells in a series of patients with MS. This study included a total of 99 patients; 44 treated with DMF and 55 patients treated with TERI. Blood counts were evaluated at baseline and every 6 months in order to track the absolute leukocyte, lymphocyte, and neutrophil counts. Twelve months after starting treatment, we observed a significant decrease in leukocytes (21.1%), lymphocytes (39.1%), and neutrophils (10%) in the DMF group. In the TERI group, leukocytes decreased by 11.1%, lymphocytes by 8.1%, and neutrophils by 15.7%. Both TERI and DMF produced a significant decrease in leukocytes during the first year of treatment and this was mainly related with a decrease in neutrophils in the TERI group and a decrease in lymphocytes in the DMF group. View Full-Text
Keywords: teriflunomide; dimethyl fumarate; multiple sclerosis; lymphopenia; immunosuppressants teriflunomide; dimethyl fumarate; multiple sclerosis; lymphopenia; immunosuppressants
Show Figures

Figure 1

MDPI and ACS Style

García-Estévez, D.A. Hematological Alterations Related to Treatment with Teriflunomide and Dimethyl Fumarate in Multiple Sclerosis. NeuroSci 2020, 1, 17-23. https://doi.org/10.3390/neurosci1010003

AMA Style

García-Estévez DA. Hematological Alterations Related to Treatment with Teriflunomide and Dimethyl Fumarate in Multiple Sclerosis. NeuroSci. 2020; 1(1):17-23. https://doi.org/10.3390/neurosci1010003

Chicago/Turabian Style

García-Estévez, Daniel A. 2020. "Hematological Alterations Related to Treatment with Teriflunomide and Dimethyl Fumarate in Multiple Sclerosis" NeuroSci 1, no. 1: 17-23. https://doi.org/10.3390/neurosci1010003

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop